- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01124162
Losartan 100 mg Tablets in Healthy Subjects Under Fasting Conditions
Randomized, 2-way Crossover, Bioequivalence Study of Losartan 100 mg Tablets and Cozaar® Administered as 1 * 100 mg Tablet in Healthy Subjects Under Fasting Conditions
Studieoversikt
Detaljert beskrivelse
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA Bioequivalence Statistical Methods
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada, H3X 2H9
- Anapharm Inc.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Non-child-bearing potential female or male.
- Non-smoker.
- 18 years of age and older.
- Capable of consent.
Non-child-bearing potential female subject:
- Post-menopausal state: absence of menses for 12 months prior to drug administration.
- Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation at least 6 months prior to drug administration.
Exclusion Criteria:
- Clinically significant illness within 4 weeks prior to the administration of the study medication.
- Clinically significant surgery within 4 weeks prior to the administration of the study medication.
- Any clinically significant abnormality found during medical screening.
- Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the subject from participating in the study.
- Abnormal laboratory tests judged clinically significant.
- Positive urine drug screen at screening.
- Positive testing for hepatitis B, hepatitis C, or HIV at screening.
- ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 100 or over 140 mmHg, diastolic blood pressure lower than 60 or over 100 bpm) at screening.
- Subjects with BMI > 30.0.
- History of significant alcohol abuse within 6 months prior to screening visit or any indication of the regular use of more than 14 units of alcohol per week (1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol).
- History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months prior to screening visit or hard drugs (such as cocaine, phencyclidine [PCP], and crack) within 1 year prior to the screening visit.
- History of allergic reactions to losartan or other related drugs.
- History of allergic reactions to heparin.
- Use of any drugs known to induce or inhibit drug metabolism within 30 days prior to administration of the study medication.
- Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
- Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowl diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the study drug.
- Any clinically significant history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic disease.
- Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products (including natural food supplements, vitamins, garlic as a supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption.
- Positive alcohol breath test at screening.
- Subjects who have used tobacco in any form within 90 days preceding study drug administration.
- Any food allergy, intolerance, restriction, or special diet that could, in the opinion of the Medical Sub-Investigator, contraindicate the subjects participation in this study.
- A dept injection or an implant of any drug within 3 months prior to administration of study medication.
Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or loss of whole blood prior to administration of the study medication as follows:
- Less than 300 mL of whole blood within 30 days
- 300 mL to 500 mL of whole blood within 45 days, or
- more than 500 mL of whole blood within 56 days prior to drug administration.
- Consumption of food or beverages containing grapefruit (e.g. fresh, canned, or frozen) within 7 days prior to administration of the study medication.
- Clinically significant history of known active hypotension or volume depletion.
- Intolerance to venipuncture.
- Clinically significant history of renal, hepatic, or cardiovascular disease, tuberculosis, epilepsy, asthma, diabetes, psychosis, or glaucoma will not be eligible for this study.
- Subjects unable to understand or unwilling to sign the Informed Consent Form.
Additional exclusion criteria for females only;
- Breast-feeding subjects.
- Positive urine pregnancy test at screening (performed for all females).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Referanselistet legemiddel
Cozaar® 100 mg tabletter
|
100 mg Tablet
Andre navn:
|
Eksperimentell: Generic Test Product
Losartan 100mg Tablets
|
100 mg Tablet
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Cmax for losartan (maksimal observert konsentrasjon av legemiddel i plasma)
Tidsramme: Blodprøver tatt over en 24 timers periode.
|
Bioekvivalens basert på Losartan Cmax.
|
Blodprøver tatt over en 24 timers periode.
|
AUC0-t for losartan (areal under konsentrasjon-tidskurven fra tid null til tidspunkt for siste målbare konsentrasjon)
Tidsramme: Blodprøver tatt over en 24 timers periode.
|
Bioekvivalens basert på Losartan AUC0-t.
|
Blodprøver tatt over en 24 timers periode.
|
AUC0-inf av Losartan (areal under konsentrasjon-tidskurven fra null til uendelig)
Tidsramme: Blodprøver tatt over en 24 timers periode.
|
Bioekvivalens basert på Losartan AUC0-inf.
|
Blodprøver tatt over en 24 timers periode.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Cmax for losartankarboksysyre (maksimal observert konsentrasjon av legemiddelstoff i plasma)
Tidsramme: Blodprøver tatt over en 24 timers periode.
|
Informasjonssammenligning av Cmax-verdier for metabolitten Losartan Carboxy Acid.
|
Blodprøver tatt over en 24 timers periode.
|
AUC0-t for Losartan Carboxy Acid (areal under konsentrasjon-tidskurven fra tid null til tidspunkt for siste målbare konsentrasjon)
Tidsramme: Blodprøver tatt over en 24 timers periode.
|
Informasjonssammenligning av AUC0-t-verdier for metabolitten Losartan Carboxy Acid.
|
Blodprøver tatt over en 24 timers periode.
|
AUC0-inf of Losartan Carboxy Acid(Area Under the Concentration-time Curve From Time Zero to Infinity)
Tidsramme: Blood samples collected over a 24 hour period.
|
Informational comparison of AUC0-inf values for the metabolite Losaran Carboxy Acid.
|
Blood samples collected over a 24 hour period.
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Richard Larouche, MD, Anapharm
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 30272
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sunn
-
Universidade do PortoFundação para a Ciência e a TecnologiaRekrutteringHealthy People-programmerPortugal
-
VA Office of Research and DevelopmentFullført
-
Universidad Católica del MauleFullført
-
University of MiamiJames and Esther King Biomedical Research ProgramAvsluttetHealthy Lifetime Ikke-røykereForente stater
-
Fundació Institut de Recerca de l'Hospital de la...FullførtHealthy People-programmerSpania
-
University of LeicesterNational Institute for Health Research, United KingdomFullførtPasienter med hjertesvikt og bevart ejeksjonsfraksjon - HFpEF | Pasienter med hjertesvikt med redusert ejeksjonsfraksjon - HFrEF | Healthy Controls Group - alders- og kjønnsmatchet
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvsluttetParkinsons sykdom | Healthy Controls Group - alders- og kjønnsmatchetFrankrike
Kliniske studier på Losartan
-
Baker Heart and Diabetes InstituteTilbaketrukket
-
National Institute of Diabetes and Digestive and...Johns Hopkins UniversityAvsluttetNAFLD - Ikke-alkoholisk fettleversykdomForente stater
-
Chinese PLA General HospitalTianjin TongRenTang Group Co., Ltd.UkjentProteinuri | GlomerulonefrittKina
-
University of South FloridaNational Cancer Institute (NCI)Fullført
-
Organon and CoAvsluttet
-
Dong Wha Pharmaceutical Co. Ltd.Fullført
-
Steadman Philippon Research InstituteRekrutteringKneartroplastikk, totaltForente stater
-
Merck Sharp & Dohme LLCFullført
-
Vifor PharmaFullførtPotensering av legemiddelinteraksjonerForente stater